

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/082096 A2

(51) International Patent Classification: Not classified

(US). AOKI, Kei, Roger [US/US]; 2 Ginger Lily Court,
Coto de Caza, CA 92679 (US).

(21) International Application Number:
PCT/US2005/006421

(74) Agent: STATHAKIS, Dean, G.; c/o Allergan, Inc., 2525
Dupont Drive, Irvine, CA 92612 (US).

(22) International Filing Date: 23 February 2005 (23.02.2005)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/547,591 24 February 2004 (24.02.2004) US

(71) Applicant (for all designated States except US): ALLER-
GAN, INC. [US/US]; 2525 Dupont Drive, Irvine, CA
92612 (US).


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FERNAN-
DEZ-SALAS, Ester [ES/US]; 1710 Rocky Road,
Fullerton, CA 92831 (US). GARY, Patton, E. [US/US];
2021 N. Beverly Place, #137, Long Beach, CA 90815

[Continued on next page]

(54) Title: BOTULINUM TOXIN SCREENING ASSAYS



(57) Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.

WO 2005/082096 A2



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.